Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 6/20 | 0.51 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028038 | 0.81 | SRD5A1 (0.46) | SRD5A1SRD5A2MEN1KMT2AEHMT2 | |
| SCHEMBL20028035 | 0.81 | SRD5A1 (0.46) | IRAK1IRAK4SRD5A1SRD5A2MEN1 | |
| SCHEMBL2361663 | 0.80 | HRH3 (0.49) | IGF1R | |
| SCHEMBL30143442 | 0.78 | EHMT2 (0.58) | EHMT2TLR9TLR7 | |
| SCHEMBL20028350 | 0.77 | PLK1 (0.38) | PDGFRBPDGFRAEHMT2PLK1TLR9 | |
| SCHEMBL20028037 | 0.76 | EHMT2 (0.39) | EHMT2PLK1TLR9TLR7ADRA1D | |
| SCHEMBL21667958 | 0.76 | EHMT2 (0.39) | EHMT2PLK1TLR9TLR7ADRA1D | |
| SCHEMBL29777944 | 0.76 | EHMT2 (0.39) | EHMT2PLK1TLR9TLR7ADRA1D | |
| SCHEMBL21667959 | 0.75 | SRD5A1 (0.40) | SRD5A1SRD5A2MEN1KMT2APLK1 | |
| SCHEMBL14382530 | 0.72 | PDE4A (0.47) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105203-A1 | SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220274961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. | 2022-09-01 | — | — | US | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| EP-3519393-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018064557-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018064557-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | SHMT1, BHMT, EHMT2 | CSF1R 3328/4885IRAK1 4665/4885IRAK4 4733/4885 |
| US-20220274961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | SHMT1, BHMT, EHMT2 | CSF1R 3328/4885IRAK1 4665/4885IRAK4 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.